Ashland Speciality Ingredients receives EXCiPACT GMP certification

Published: 30-May-2017
Ingredients Regulatory

Certification as pharmaceutical excipient suppliers for Belgium site

Ashland Speciality Ingredients site in Doel, Belgium has recently been awarded an EXCiPACT GMP Certificate from SGS, one of EXCIPACT’s internationally-recognised Certification Bodies.

The Certificate demonstrates that the Ashland Speciality Ingredients (ASI) site in Doel, Belgium, manufactures pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard.

Its scope covers the production of methylcellulose (MC), hydroxypropylmethylcellulose (HPMC) and methylhydroxyethylcellulose (MHEC) as pharmaceutical excipients.

  • Companies:
  • Ashland
  • EXCiPACT
See more

You may also like

Regulatory

Illinois Corn Processing site receives EXCiPACT certification

Read more
The certificate demonstrates the site manufactures ethyl alcohol intended for use as a pharmaceutical excipient according to the 2017 EXCiPACT GMP certification standard

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  4. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  5. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Illinois Corn Processing site receives EXCiPACT certification

The certificate demonstrates the site manufactures ethyl alcohol intended for use as a pharmaceutical excipient according to the 2017 EXCiPACT GMP certification standard
Regulatory

JRS Pharma and Gujurat Microwax achieve EXCiPACT certification

EXCiPACT has certified sites in 21 countries to date including the UK, US, Japan and China
Ingredients

Colorcon Westpoint site gains EXCiPACT GMP and GDP Certificate from SGS

Site in Pennsylvania manufactures and distributes lake pigments for use as pharmaceutical excipients
Ingredients

Ashland launches new excipient solutions for improved drug delivery

Ashland will premieres the new products at upcoming pharma shows at CPhI in Frankfurt, Germany, and AAPS PharmSci360, San Antonio, Texas
Regulatory

SGS certifies Valtris Speciality Chemical site as GMP

Certification body of EXCiPACT, SGS, has certified that the Cleveland site manufactures metal stearate to GMP standard
Manufacturing

Qualicaps Romania gains EXCiPACT GMP certification

The certification scope covers the manufacture of gelatin capsule shells for the pharmaceutical and consumer health industries
Regulatory

SGS certifies Dow's Stade site with EXCiPACT GMP standard

The certificate demonstrates that this site manufactures pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard
Subscribe now